Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dabuzalgron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 9/20 | 0.98 |
| ▸ | NISCH | Q9Y2I1 | 9/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dabuzalgron SCHEMBL5203336 | 0.99 | ADRA1A (1.00) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| Dabuzalgron SCHEMBL19285840 | 0.98 | ADRA1A (0.98) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL5201030 | 0.88 | ADRA1A (0.80) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL5203525 | 0.87 | ADRA1A (0.75) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL5200474 | 0.86 | ADRA1A (0.77) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL22596705 | 0.83 | ADRA1A (0.73) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL5201322 | 0.80 | ADRA1A (0.65) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL5204186 | 0.79 | ADRA1A (0.67) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL5202260 | 0.79 | ADRA1A (0.66) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL5206476 | 0.78 | ADRA1A (0.62) | ADRA1ANISCHHTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590107-B2 | Methods for treating neurological disorders with α1A-AR partial agonists | CURASEN THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | claimed |
| US-20250188060-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4499070-A1 | ALPHA 1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | Curasen Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023183394-A1 | ALPHA 1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4204404-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | Curasen Therapeutics, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11590107-B2 | Methods for treating neurological disorders with α1A-AR partial agonists | CURASEN THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220401415-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH ALPHA1A-AR PARTIAL AGONISTS | CURASEN THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4048263-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH ALPHA 1A-AR PARTIAL AGONISTS | Curasen Therapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2022047052-A1 | α1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021081292-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH α1A-AR PARTIAL AGONISTS | CURASEN THERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20210121444-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS | CURASEN THERAPEUTICS, INC. | 2021-04-29 | — | — | US | disclosed |
| EP-0887346-B1 | N-Phenyl-alkylsulfonamide derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401415-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH ALPHA1A-AR PARTIAL AGONISTS | ADRA2A, ADRA1A, HTR1A | ADRA1A 2/4885NISCH 1973/4885HTR1A 3/4885 |
| US-11590107-B2 | Methods for treating neurological disorders with α1A-AR partial agonists | ADRA2A, ADRA1A, HTR1A | ADRA1A 2/4885NISCH 2025/4885HTR1A 3/4885 |
| US-20250188060-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRB1, ADRA1A, ADRA1D | ADRA1A 2/4885NISCH 1791/4885HTR1A 41/4885 |
| US-20210121444-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS | ADRA2A, ADRA1A, ADORA2A | ADRA1A 2/4885NISCH 1270/4885HTR1A 4/4885 |
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRA1A, ADRB1, ADRA1D | ADRA1A 1/4885NISCH 1881/4885HTR1A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.